Zuwała-Jagiełło Jolanta
Medical University of Wrocław, Department of Pharmaceutical Biochemistry, Poland.
Pol Merkur Lekarski. 2009 Aug;27(158):152-6.
Nonenzymatic modification of proteins by reducing sugars, a process that is also known as the Maillard reaction, leads to the formation of advanced glycation end products (advanced glycation end-products--AGEs) in vivo. There is a growing body of evidence that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, and are thus involved in the pathogenesis of various diseases such as diabetic vascular complications, neurodegenerative diseases, renal failure, and liver cirrhosis. Therefore, inhibition of AGEs formation may be a promising target for therapeutic intervention in AGEs-related disorders. There is a growing body of evidence that AGEs and their receptor (receptor for advanced glycation endproducts--RAGE) axis are also implicated in the pathogenesis of various diseases. In the former part of this paper, we discuss several types of AGEs inhibitors and their therapeutic implications in diseases. Then we summarize in the latter part of this review recent findings regarding pathophysiological roles in diseases of RAGE and soluble RAGE and discuss their potential usefulness as therapeutic targets.
蛋白质被还原糖进行非酶修饰，这一过程也被称为美拉德反应，会在体内导致晚期糖基化终末产物（晚期糖基化终产物——AGEs）的形成。越来越多的证据表明，AGEs的形成和积累在正常衰老过程中会持续进展，而在糖尿病状态下其进展速度会极快加速，因此参与了多种疾病的发病机制，如糖尿病血管并发症、神经退行性疾病、肾衰竭和肝硬化。所以，抑制AGEs的形成可能是针对与AGEs相关疾病进行治疗干预的一个有前景的靶点。越来越多的证据表明，AGEs及其受体（晚期糖基化终末产物受体——RAGE）轴也与多种疾病的发病机制有关。在本文的前半部分，我们讨论了几种类型的AGEs抑制剂及其在疾病中的治疗意义。然后在本综述的后半部分，我们总结了关于RAGE和可溶性RAGE在疾病中的病理生理作用的最新发现，并讨论了它们作为治疗靶点的潜在用途。
